Spinal cord stimulation in the treatment of non-reconstructable stable critical leg ischaemia: Results of the European Peripheral Vascular Disease Outcome Study (SCS-EPOS)  by Amann, W. et al.
Spinal Cord Stimulation in the Treatment of Non-reconstructable
Stable Critical Leg Ischaemia: Results of the European Peripheral
Vascular Disease Outcome Study (SCS-EPOS)
W. Amann1, P. Berg2, P. Gersbach3, J. Gamain4, J. H. Raphael5 and D. Th. Ubbink6,
for the SCS-EPOS Study Group
1Department of Vascular Surgery, University Hospital, Graz, Austria, 2Department of Vascular Surgery, Luxembourg
Hospital, Luxembourg City, Luxembourg, 3Department of Cardiovascular Surgery, University Hospital,
Lausanne, Switzerland, 4Department of Anaesthesiology, University Hospital, Amiens, France, 5Department of
Pain Management, Dudley Group of Hospitals NHS Trust, Dudley, U.K., 6Academic Medical Center,
Department of Vascular Surgery, Amsterdam, The Netherlands
Objective: to determine the effect of spinal cord stimulation (SCS) on limb survival in patients with non-reconstructable
critical leg ischaemia, and the value of patient selection on the basis of transcutaneous oxygen pressure (TcpO2) measure-
ments and trial screening.
Design: a prospective, controlled, European multicentre study.
Methods: non-reconstructable patients with stable critical leg ischaemia were divided into three groups. The SCS-Match
group comprised patients with a baseline forefoot TcpO2 of 530 mmHg and both sufficient pain relief and sufficient
paraesthesia coverage (475%) after a test stimulation period of at least 72 h. If baseline TcpO2 was 510 mmHg, the TcpO2
should have exceeded 20 mmHg after test stimulation. The SCS-Match group was compared with patients not meeting these
criteria, who were treated either with SCS (SCS-No-Match) or without SCS (No-SCS).
Results: at baseline, the mean (+SD) supine TcpO2 was 14.9+ 8.3 mmHg in the SCS-Match group (n 41),
11.3+ 13.3 mmHg in the SCS-No-Match group (n 32) and 15.3+ 17.1 mmHg in the No-SCS group (n 39). In the
SCS-Match group a significant improvement in pain relief (p5 0.005) and TcpO2 (p5 0.001) was seen. After 12 months,
cumulative limb survival of patients treated with SCS was significantly better than that of patients not treated with SCS
(p5 0.03), and limb survival in the SCS-Match group was significantly higher (p5 0.03) than that in the SCS-No-Match
and No-SCS groups (78, 55 and 45%, respectively).
Conclusion: SCS treatment of non-reconstructable critical leg ischaemia provides a significantly better limb survival rate
compared with conservative treatment. Patient selection based on TcpO2 and the results of trial screening further increase
the probability of limb survival after SCS therapy.
Key Words: Critical leg ischaemia; Spinal cord stimulation; Neuromodulation; Limb survival; Transcutaneous oxygen
pressure.
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The treatment of patients with unreconstructable crit-
ical leg ischaemia (CLI) remains challenging with
most medically treated progressing to amputation.1±4
Electrical stimulation of the dorsal column (spinal
cord stimulation (SCS)) was first described in 1965,5
and is a well-accepted treatment for neurogenic
pain. The first publication concerning patients with
peripheral vascular disease appeared in 1976,6 withPlease address all correspondence to: W. Amann, Department of
Vascular Surgery, University Hospital Graz, Auenbruggerplatz 15,
A-8036 Graz, Austria.
1078±5884/03/030280 07 $35.00/0 # 2003 Elsevier Science Ltd. Alseveral recent studies reporting positive microcircula-
tory effects.7±10 pain relief and improved wound heal-
ing.11±15 However, SCS has not been shown in trials
to prevention amputation,13,16,17 and cannot as yet
be recommended as standard treatment for non-
reconstructable CLI.2
A transcutaneous oxygen pressure (TcpO2)
510 mmHg is associated with a high amputation
rate18 while an increase of TcpO2 following treatment
often predicts limb salvage.8 The Dutch multicentre
trial16 suggested that SCS was associated with a
reduction in amputation in patients with a TcpO2 of
10±30 mmHg10. Here, the effect of TcpO2 on the results
of SCS is further studied.l rights reserved.
Patients and Methods
Fig. 1. Flow chart for patient selection based on TcpO2.
Spinal Cord Stimulation 281This was a prospective, controlled, 17-centre
European study conducted between September 1999
and January 2002. Randomisation was not considered
feasible owing to the relatively small number of patients
fulfilling the inclusion criteria. Ethical committee
approvals were obtained. The general objective was
to evaluate the clinical outcomes of SCS in a selected
group of patients with non-reconstructable peripheral
vascular disease. The primary endpoint was limb sur-
vival, defined as a lack of amputation of the target leg
in or above the level of the ankle during the follow-up
period. Secondary objectives were pain relief, wound
healing and quality of life in the patients meeting the
inclusion criteria, and the prognostic value of TcpO2.
Eligible patients had chronic, stable CLI19 and were
not suitable for vascular reconstruction according to
the responsibility of a vascular surgeon. Other inclu-
sion criteria were informed consent, the intention to
treat the target leg only and the cognitive capability of
the patient to use the therapy. Exclusion criteria were
peripheral arterial occlusive disease other than that
caused by atherosclerosis, such as Buerger's or Ray-
naud's disease, previous major amputation in the tar-
get leg, lesions with a diameter of 43 cm, wet
gangrene or deep infections in the target leg, esti-
mated life expectancy of 5 12 months and contrain-
dications for the implantation of a stimulator (such as
implanted cardiac pacemaker, pregnancy or spinal
pathology). Diabetes mellitus was not a contraindica-
tion. Patients were allocated to the SCS-Match group if
their forefoot TcpO2 (measured with the TCM 30
device of Radiometer, Copenhagen, Denmark) in
the supine position was 530 mmHg and if they
responded with adequate pain relief and paraesthesia
coverage (at least 75% of the painful area) after a test
stimulation period of at least 72 h. If the baseline fore-
foot TcpO2 was 5 10 mmHg, the TcpO2 should have
increased above 20 mmHg after test stimulation (with
adequate pain relief and paraesthesia coverage) in
order for the patient to be included in the SCS-Match
group. If not (e.g. initial TcpO24 30 mmHg or
remaining at 510 mmHg after test stimulation), the
treatment was at the discretion of the physician, being
either a continuation of SCS (SCS-No-Match group) or
conservative treatment (No-SCS group) (Fig. 1). These
cut-off values for TcpO2 were based on prior publica-
tions on TcpO2 as a predictor for the severity of leg
ischaemia and for an imminent major amputation.10,18
Treatment comprised medical optimisation includ-
ing analgesics, anticoagulants, vasoactive agents, local
wound care, and antibiotics if indicated. If the patient
was allotted SCS, the system was implanted in twostages as a period of test stimulation is known to be
helpful in selecting patients who would respond
favourably to this therapy. The quadripolar lead
(Medtronic Inc., MN, U.S.A.) was inserted under
polarographic control and antibiotic prophylaxis via
a lumbar puncture between the level of the second
and fifth lumbar vertebrae. The tip of the lead was
moved upwards between the eighth thoracic and first
lumbar vertebrae. The lead was then connected to an
external stimulator. The exact position of the lead was
ascertained by the presence of pleasant paraesthesiae
in the area of pain under stimulation. The procedure
was performed under local anaesthesia to enable feed-
back from the patient concerning the extent of paraes-
thesia coverage in the target leg. All patients who
fulfilled the inclusion criteria underwent a trial
screening period of stimulation after lead implant-
ation. Patients who met the final inclusion criteria at
the end of the trial screening period (SCS-MatchEur J Vasc Endovasc Surg Vol 26, September 2003
Table 1. Demographic data and patient history for the SCS-Match
group (n 41).
Age, mean SD (range) (years) 68 13 (37±88)
Sex (% male) 65.9
Medical History (%)
Hypertension 48.8
Diabetes 31.7
Angina pectoris 26.8
Myocardial infarction 29.3
Transient ischaemic attack 14.6
Cerebrovascular accident 19.5
Smoked/smoking 63.4
Vascular history (%)
Central vascular reconstruction 24.4
Peripheral vascular reconstruction 65.9
Sympathetic block 26.8
Minor amputation on target leg 9.8
Major amputation on contralateral leg 7.3
Median time from diagnosis to baseline (months)
Peripheral arterial occlusive disease 13.7
Critical leg ischaemia 2.3
Table 2. Reasons for failed enrolment in control groups.
SCS-No-Match
(n 32)
No-SCS
(n 39)
TcpO2 too low after trial screening 21 10
TcpO2 too high at baseline 5 9
Medical decision not to include 0 8
Patient cognitively not capable
to enter study
1 1
No patient consent 2 6
Failure to achieve adequate
paraesthesiae
0 1
No adequate pain relief 0 1
Contraindication for SCS therapy 2 2
Other 1  1 y
Unreliable TcpO2 values due to spastic disease.
yExtension broken after trial screening implant and impossibility to
re-implant due to anatomical reasons.
282 W. Amann et al.group) and those who did not but in whom the treat-
ing surgeon considered continuation appropriate
(SCS-No-Match group) received an extension cable
and internal pulse generator (IPG Itrel or Synergy;
Medtronic Inc., MN, U.S.A.). The flow chart for
patient selection is given in Figure 1. The remaining
patients were treated conventionally (No-SCS group).
Clinical and technical follow-up visits for the SCS-
Match group were at 3, 6, 12 and 18 months. The
medication used for the treatment of ischaemic pain
as well as limb salvage, pain reduction, quality of life
and healing of ischaemic lesions were documented.
Doppler ankle blood pressures were assessed and
measurements of TcpO2 were performed at least at 6
and 12 months. The patients were asked to fill out a
questionnaire relating to the duration and intensity of
ischaemic pain (visual analogue scale [VAS] score)
and their satisfaction with the therapy, and also to
complete the SF-12TM Health Survey. Patients in the
SCS-No-Match and No-SCS groups had a follow-up
visit only at 12 months (or study termination) to assess
leg status. This 12-month period was considered
adequate, given the high incidence of amputation
and death.2 Complications leading to inadequate
stimulation or temporary removal of the system
resulted in the patient's receipt of only standard treat-
ment, but the patient would remain in the SCS group
according to the intention-to-treat principle.
The level of significance for all analyses was 5%.
The estimated curve of the probability of the limb
survival time was generated by the Kaplan±Meier
method. In the limb survival analysis, patients were
censored at study termination. The difference between
survival curves was analysed using a log rank test.
Pain relief from pre- to post-implant was expressed on
a 0±10 score VAS. Pain relief between baseline and
follow-up, TcpO2 evolution and within-group change
in TcpO2 were analysed by a paired t-test. The
between-group difference in baseline TcpO2 was ana-
lysed by a t-test, and the between-group difference in
baseline Fontaine stage was analysed by a chi-square
test. The between-group change in TcpO2 from pre- to
post-trial screening was analysed by an ANCOVA in
which the baseline TcpO2 was used as a covariate. The
number of patients with or without a Fontaine scale of
IV between baseline and 12 months and the number
of patients taking or not taking narcotics between
baseline and 12 months were analysed with a
McNemar test.
Results
One hundred and twelve patients were eligible
according to their clinical appearance and were
Eur J Vasc Endovasc Surg Vol 26, September 2003analysed further. Of these, 52% belonged to stage III
and 48% to stage IV according to Fontaine. All patients
were considered unsuitable for any vascular recon-
struction according to the judgement of a vascular
surgeon: 14.6% had no autologous vein, 51.2% did
not have a suitable artery and 26.8% had neither of
these. The remaining 7.3% were unable to undergo
vascular reconstruction due to other reasons, such as
a contraindication for anaesthesia. Of the 112 patients,
41 fulfilled all criteria for enrollment into the study
and entered the SCS-Match group. Demographic data
and medical and vascular history at baseline for this
group are given in Table 1. Angiographic assessment
of the patients in the SCS-Match group showed that
15.0% had central stenoses, 69.2% had stenoses of
450% of vessels or occlusion in the upper leg, and
86.8% had occlusion of at least one calf vessel. The
mean Doppler-derived ankle/brachial pressure index
in the SCS-Match group was 29%.
Table 3. Fontaine scale at baseline (no significant differences between groups) and TcpO2 at baseline and after
trial screening.
SCS-Match SCS-No-Match No-SCS
Fontaine stage (%)
Stage III 43.9 46.9 64.1
Stage IV 56.1 53.1 35.9
Mean sd supine TcpO2 (mmHg)
Baseline  14.9 8.3 (n  41) 11.3 13.3 (n 30) 15.3 17.1 (n 34)
TcpO2 after trial screening 30.9 11.2 (n 41) 12.7 13.6 (n 28) 6.5 6.1 (n 10)
DTcpO2 (trial screening ± baseline) y 15.9 10.4 (n 41) 3.4 7.0 (n 27) 0.7 6.4 (n 10)
p-value of DTcpO2 (trial screening ± baseline) 50.0001 0.02 0.74
No significant difference between groups.
y Significant difference in TcpO2 from pre- to post-trial screening between all three groups using an ANCOVA model
(p5 0.0001), between SCS-Match and SCS-No-Match groups and between SCS-Match and No-SCS groups
(p5 0.0001); no significant difference (p 0.334) between
SCS-No-Match and No-SCS groups.
Fig. 2. TcpO2 at baseline and during SCS treatment. This graph
shows the mean values of supine (solid line) and leg-dependent
(dashed line) TcpO2 over time. The numbers represent actual TcpO2
values at the indicated time points. The rapid increase seems to be
stable over time. The numbers of patients at each time point are as
follows (n supine/n leg-dependent): baseline, 41/40; trial screening,
41/37; 3 months, 11/10; 6 months, 27/25; 12 months, 21/20. The
numbers of patients at 3 months are low as this test was not actually
required in the study protocol. TcpO2 at trial screening, 3, 6 and 12
months is significantly greater compared with baseline for the
supine and the leg-dependent groups (p5 0.01), except in leg-
dependent position at 3 months (not significant) and at 6 months
(p5 0.03).
Table 4. SCS-related adverse events in the SCS-Match group.
Event type Occurrence
No. of
events
No. of
patients 
Undesirable change in stimulation 6 4
Lead migration 5 4
IPG battery end of life 5 4
Infection 2y 2
Other 1 1
Total 19 z 12
IPG, implantable pulse generator. Some patients had more than one event/event type.
yOne infection at the lead-extension connection site, another at the
IPG pocket site.
z Surgery was needed to solve 15 of the 19 events.
Spinal Cord Stimulation 283The remaining 71 patients, who violated one or
more inclusion criteria, were allotted to two control
groups and received either stimulation therapy (SCS-
No-Match, n 32) or conventional conservative treat-
ment alone (No-SCS, n 39). The reasons for failed
enrollment are listed in Table 2. The Fontaine stage
and TcpO2 at baseline were similar between the SCS-
Match group and both control groups, as indicated in
Table 3.
After the period of test stimulation (mean duration
5.6 3.8 days), supine TcpO2 in the SCS-Match group
(3111.2 mmHg) was significantly (p5 0.0001) higher
than at baseline and remained stable during the
follow-up measurements (Fig. 2). Relief of pain couldbe achieved in terms of both duration and intensity;
the difference between baseline and follow-up was
statistically significant (p5 0.005). The percentage
of patients using narcotic analgesics decreased sub-
stantially (although not significantly) from 58% at
baseline to 29% during SCS treatment. The SF-12
data confirmed no worsening of the physical and
mental component score. After 12 months, 43% of
the SCS-Match patients had improved from Fontaine
stage III or IV to stage I or II. Wound healing was also
observed, as the percentage of patients with Fontaine
stage IV at baseline substantially (although not signifi-
cantly) decreased from 56 to 29% at 12 months. SCS-
related adverse events occurred in 12 patients and are
listed in Table 4. During follow-up, 97±100% of the
SCS-Match patients said that if they had to chose
their treatment again based on their experience so far
they would have agreed to this stimulation therapy.
At 12 months, the number of major amputations (%)
in the SCS-Match, SCS-No-Match and No-SCS groups
were 8 (20%), 13 (41%) and 18 (46%), respectively.
Figure 3 shows Kaplan±Meier plots for limb survival
comparing the three study groups. CumulativeEur J Vasc Endovasc Surg Vol 26, September 2003
Fig. 4. Cumulative limb survival of SCS-Match plus SCS-No-Match
(solid line) vs No-SCS (dashed line) groups. The vertical lines A, B
and C represent 3, 6 and 12 months, respectively. p5 0.003.
Fig. 3. Cumulative limb survival of the SCS-Match (solid line) vs
SCS-No-Match (dashed line) vs No-SCS (hatched line) groups. The
vertical lines A, B and C represent 3, 6 and 12 months, respectively.p5 0.03.
Fig. 5. Cumulative limb survival of the SCS-Match (solid line) vs
SCS-No-Match (dashed line) vs No-SCS (hatched line) groups with
TcpO2 values between 0 and 30 mmHg at baseline. For SCS-No-
Match and No-SCS, the survival curves are shown as different
grey dotted lines when the standard error exceeds 10%. The vertical
lines A, B and C represent 3, 6 and 12 months, respectively.p5 0.03; p5 0.002.
284 W. Amann et al.limb survival after 12 months in the SCS-Match,
SCS-No-Match and No-SCS groups were 78, 55 and
45%, respectively. Limb survival in all patients receiv-
ing SCS treatment (SCS-Match SCS-No-Match) was
better than in patients with medical treatment only,
illustrating a beneficial effect of SCS on limb survival
(Fig. 4, p5 0.003). Furthermore, limb survival in the
SCS-Match group was significantly better compared
with the other groups (p5 0.03 in both cases), illus-
trating that selection on the basis of TcpO2 and trial
screening improved the effectiveness of SCS.
The difference in limb survival in the SCS-
No-Match vs No-SCS groups was not significant
(p 0.1085). However, SCS-Match patients were also
compared with a subpopulation of patients from each
of the other two groups in which patients with a
TcpO2 of 430 mmHg were excluded (and were likelyEur J Vasc Endovasc Surg Vol 26, September 2003to have a better outcome than those in the SCS-Match
group). This showed an even more significant differ-
ence in limb survival between the SCS-Match group
and the subgroups (p5 0.002 in both cases) (Fig. 5).
Also, the difference in limb survival between these
subpopulations of SCS-No-Match and No-SCS
patients was significant (p5 0.03). At 12 months, the
numbers of major amputations (%) in the subpopula-
tions of the SCS-No-Match and No-SCS groups were
13 (52%) and 15 (60%), respectively.
Sixteen patients (eight SCS-Match, three SCS-No-
Match and five No-SCS) were censored after a mean
follow-up duration of 168 days, as they underwent
arterial reconstruction as a last resort additional treat-
ment when their clinical condition worsened. Their
clinical outcome did not appear to be better than
those who did not undergo the operation. Other
patients were censored at study termination.
Discussion
The study suggests that patients with unreconstruct-
able CLI can benefit from SCS not only in terms of
ischaemic pain relief and wound healing but also,
unlike previous studies, limb salvage.13,16,17 This
difference may be due to three factors. Firstly, in the
previous studies the local microcirculatory perfusion,
which is the ultimate cause for ischaemic tissue loss,
was not taken into account. A poor local microcircula-
tion may indicate an already exhausted healing poten-
tial that is beyond repair and will ultimately lead
to a major amputation, whereas in the presence of
a relatively good local microvascular perfusion
Spinal Cord Stimulation 285ischaemic ulcers may heal without the need for a
major intervention.10,18 In the present study, selection
of patients with a fair local microcirculation on the
basis of their local TcpO2 (10±30 mmHg), and those
with a poor TcpO2 (510 mmHg) who still showed at
least some reserve capacity (increasing to at least
20 mmHg) after test stimulation, did indeed result in
an enhanced effect of SCS on limb survival. The TcpO2
value used here as a selection criterion was measured
in the supine position. Other investigators have pro-
posed TcpO2 parameters derived from postural
changes to better appreciate the reserve capacity of
the local microcirculation, which could improve
patient selection.9,20 The supine TcpO2 used here,
which is most commonly used in routine measure-
ments, readily detected a good response to SCS,
which persisted during the follow-up period. Further
research is now focusing on which TcpO2 parameters
can select patients who will benefit the most from SCS.
Second, the period of trial stimulation may facilitate
selection of patients who will respond best to SCS
treatment. In some previous studies no trial stimula-
tion was applied, mainly because of a lack of objective
measures for the response to SCS and also to avoid an
additional infection risk.13,16 In the present study,
however, no higher infection rate was observed with
delayed implantation of the pulse generator. Repeat-
ing the TcpO2 measurement after test stimulation
could detect an improved local oxygen supply. Fur-
thermore, delayed implantation allows for the assess-
ment of sufficient pain relief when the paraesthesiae
are in the painful area and saves costs when perman-
ent implantation is not indicated.
Third, the non-randomised study design might
have caused a selection bias towards those likely to
benefit from the treatment. However, the three groups
did not differ significantly at baseline and did not
differ from the patient groups investigated in previous
randomised controlled trials, which yielded similar
limb survival rates.13,16,17 Another possible bias may
come from the fact that the values of the outcome
measures (e.g. TcpO2, Fontaine stage, VAS, SF-12) of
those undergoing an amputation were not carried
forward in the calculations. This might lead to an over-
estimation of clinical outcomes at later time points.
The 78% limb survival in non-reconstructable
patients found in the present study is very much
comparable to the success rates of infrainguinal vas-
cular reconstructions,21 and even better if the results
of distal reconstructions with synthetic and alternative
vascular grafts in the case of a lack of autologous vein
are considered. The decision as to whether or not a
patient with critical arterial insufficiency of infra-
genual and crural vessels is reconstructable ischallenging, and the success rate of extreme distal
revascularisations is often disappointing.22±25 In our
study, this decision was always taken by an experi-
enced vascular surgeon. Nevertheless, a few patients
underwent a last-resort arterial reconstruction during
the follow-up period. Considering that the clinical
situation of these patients did not improve substan-
tially, the prediction of successful reconstructability in
severe peripheral arterial occlusions will remain diffi-
cult and the outcome of vascular reconstructions as a
last therapeutic option is not expected to be better
than alternative approaches.
The need to assess the local microcirculation and the
possibility of procedure-related adverse events (which
sometimes require reintervention), such as lead
migration, undesirable changes in stimulation, end of
life of the stimulator battery, and infections, suggests
that the use of SCS should be recommended in centres
that are familiar with this method and that have the
possibility of microcirculatory investigation based on
TcpO2 measurements.
In conclusion, although the study is not randomised
our data suggest that, in a pre-selected group of
patients with critical limb ischaemia in whom vascu-
lar reconstruction is impossible due to a lack of an
autologous vein or distal arterial run-off, SCS can
improve limb survival to avoid or postpone a major
amputation, relieve ischaemic pain and improve
microcirculation. Furthermore, selection of patients
on the basis of their local microcirculation and a posi-
tive response to a period of trial screening can further
improve the probability of limb salvage. We therefore
recommend a test stimulation period with repeated
TcpO2 measurements (pre- and post-trial screening).
If there is evidence of pain relief (through adequate
paraesthesia coverage) and a positive microcirculatory
response to SCS, final implantation of the pulse gen-
erator is justified. To confirm these findings, a rando-
mised study to compare patients selected on the basis
of TcpO2 measurements with or without SCS treat-
ment should be performed.
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